Literature DB >> 33622888

An Institutional Audit of Maximum Heart Dose in Patients Treated With Palliative Radiotherapy for Non-small Cell Lung Cancer.

Carsten Nieder1,2, Kristian S Imingen3,2.   

Abstract

BACKGROUND/AIM: Recent studies suggested that high unintended radiation doses to the heart may reduce survival of patients with non-small-cell lung cancer (NSCLC) irradiated with curative intent. In the palliative setting, limited information is available. Therefore, we analyzed a single-institution cohort of 165 patients. PATIENTS AND METHODS: Patients in this retrospective study received palliative (chemo)radiotherapy (at least 30 Gy). Typical radiation doses were 10-13 fractions of 3 Gy and 15 fractions of 2.8 Gy. Heart dose constraints were not employed during treatment planning. The maximum dose to 1 cc of the heart was registered and converted into the equivalent dose in 2-Gy fractions (EQD2).
RESULTS: The median heart dose (maximum to 1 cc) was 26 Gy (range=11-42 Gy). This dose corresponded to 28-108% of the prescription dose. After conversion into EQD2, the median maximum heart dose to 1 cc was 26 Gy, range=10-58 Gy). Neither higher T-stage nor higher N-stage predicted for higher maximum heart EQD2. The maximum heart EQD2 was not associated with overall survival.
CONCLUSION: The current practice of focusing on sparing of lungs and esophagus appears acceptable in the context of palliative regimes. To further strengthen this strategy, additional studies looking at cardiac substructures and other dosimetric variables such as mean dose are warranted. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Radiotherapy; dosimetric analysis; heart; non-small cell lung cancer; palliative treatment

Year:  2021        PMID: 33622888      PMCID: PMC8045074          DOI: 10.21873/invivo.12336

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  21 in total

1.  A Four-Tiered Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer.

Authors:  Carsten Nieder; Terje Tollåli; Ellinor Haukland; Anne Reigstad; Liv Randi Flatøy; Astrid Dalhaug
Journal:  Cancer Invest       Date:  2018-01-10       Impact factor: 2.176

2.  Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer.

Authors:  Hans Paul van der Laan; R Melissa Anakotta; Erik W Korevaar; Margriet Dieters; J Fred Ubbels; Robin Wijsman; Nanna M Sijtsema; Stefan Both; Johannes A Langendijk; Christina T Muijs; Antje C Knopf
Journal:  Acta Oncol       Date:  2019-09-26       Impact factor: 4.089

3.  Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity.

Authors:  Marian Reinfuss; Anna Mucha-Małecka; Tomasz Walasek; Paweł Blecharz; Jerzy Jakubowicz; Piotr Skotnicki; Teresa Kowalska
Journal:  Lung Cancer       Date:  2010-07-31       Impact factor: 5.705

4.  Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer.

Authors:  Katelyn M Atkins; Bhupendra Rawal; Tafadzwa L Chaunzwa; Nayan Lamba; Danielle S Bitterman; Christopher L Williams; David E Kozono; Elizabeth H Baldini; Aileen B Chen; Paul L Nguyen; Anthony V D'Amico; Anju Nohria; Udo Hoffmann; Hugo J W L Aerts; Raymond H Mak
Journal:  J Am Coll Cardiol       Date:  2019-06-18       Impact factor: 24.094

5.  A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 GY: results of a randomized equivalence study.

Authors:  U Nestle; C Nieder; K Walter; U Abel; D Ukena; G W Sybrecht; K Schnabel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

6.  Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival.

Authors:  Alan McWilliam; Jonathan Khalifa; Eliana Vasquez Osorio; Kathryn Banfill; Azadeh Abravan; Corinne Faivre-Finn; Marcel van Herk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-06-23       Impact factor: 7.038

7.  Patient's quality of life after high-dose radiation therapy for thoracic carcinomas : Changes over time and influence on clinical outcome.

Authors:  Christina Schröder; Rita Engenhart-Cabillic; Hilke Vorwerk; Michael Schmidt; Winfried Huhnt; Eyck Blank; Dietrich Sidow; André Buchali
Journal:  Strahlenther Onkol       Date:  2016-10-27       Impact factor: 3.621

Review 8.  Radiation-Induced Lung Injury: Assessment and Management.

Authors:  Alexander N Hanania; Walker Mainwaring; Yohannes T Ghebre; Nicola A Hanania; Michelle Ludwig
Journal:  Chest       Date:  2019-04-15       Impact factor: 9.410

9.  Impact of small residual setup errors after image guidance on heart dose and survival in non-small cell lung cancer treated with curative-intent radiotherapy.

Authors:  Corinne Johnson-Hart; Gareth Price; Alan McWilliam; Andrew Green; Corinne Faivre-Finn; Marcel van Herk
Journal:  Radiother Oncol       Date:  2020-04-14       Impact factor: 6.280

10.  Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.

Authors:  H H Strøm; R M Bremnes; S H Sundstrøm; N Helbekkmo; O Fløtten; U Aasebø
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.